Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Price Performance

Shares of APTO opened at $0.36 on Friday. The business has a 50-day moving average of $0.40 and a 200-day moving average of $0.76. The company has a market capitalization of $6.60 million, a price-to-earnings ratio of -0.06 and a beta of 1.26. Aptose Biosciences has a 1 year low of $0.33 and a 1 year high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.